Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288150 | 0.82 | GRIN2B (0.51) | DYRK1ADYRK1BGRIN2BGRIN1CYP2A6 | |
| SCHEMBL17546562 | 0.79 | DYRK1A (0.68) | DYRK1ADYRK1BGRIN2BGRIN1CYP2A6 | |
| SCHEMBL26824371 | 0.75 | DYRK1A (0.37) | DYRK1ADYRK1B | |
| SCHEMBL9773308 | 0.74 | DAO (0.44) | GRIN2BGRIN1CHEK1SLC6A7 | |
| SCHEMBL695227 | 0.71 | SLC6A7 (0.41) | CHEK1SLC6A7 | |
| SCHEMBL29631040 | 0.71 | DYRK1A (0.54) | DYRK1ADYRK1BGRIN2BGRIN1SLC6A7 | |
| SCHEMBL72613 | 0.70 | AR (0.43) | DYRK1ADYRK1BGRIN2BGRIN1CYP2A6 | |
| SCHEMBL12031414 | 0.70 | DAO (0.34) | GRIN2BGRIN1CHEK1SLC6A7 | |
| SCHEMBL28373191 | 0.68 | GSK3B (0.42) | GRIN2BGRIN1CYP2A6 | |
| SCHEMBL28147641 | 0.68 | HDAC1 (0.40) | GRIN2BCYP2A6CHEK1SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-2184994-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983831-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | DYRK1A 4328/4885DYRK1B 4457/4885GRIN2B 3343/4885 |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | DYRK1A 2498/4885DYRK1B 2890/4885GRIN2B 4400/4885 |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | DYRK1A 4328/4885DYRK1B 4457/4885GRIN2B 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.